These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 14583762)
21. Risk of thyroid cancer in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study. Taylor AJ; Croft AP; Palace AM; Winter DL; Reulen RC; Stiller CA; Stevens MC; Hawkins MM Int J Cancer; 2009 Nov; 125(10):2400-5. PubMed ID: 19610069 [TBL] [Abstract][Full Text] [Related]
22. Is radioactive iodine- 131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer? Souza MC; Momesso DP; Vaisman F; Vieira Neto L; Martins RA; Corbo R; Vaisman M Arch Endocrinol Metab; 2016 Feb; 60(1):9-15. PubMed ID: 26222230 [TBL] [Abstract][Full Text] [Related]
23. Thyroid adenomas after solid cancer in childhood. Haddy N; El-Fayech C; Guibout C; Adjadj E; Thomas-Teinturier C; Oberlin O; Veres C; Pacquement H; Jackson A; Munzer M; N'Guyen TD; Bondiau PY; Berchery D; Laprie A; Bridier A; Lefkopoulos D; Schlumberger M; Rubino C; Diallo I; de Vathaire F Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):e209-15. PubMed ID: 22672756 [TBL] [Abstract][Full Text] [Related]
24. Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study. Lin CY; Lin CL; Huang WS; Kao CH J Nucl Med; 2016 May; 57(5):685-90. PubMed ID: 26719377 [TBL] [Abstract][Full Text] [Related]
25. Childhood thyroid cancers and radioactive iodine therapy: necessity of precautious radiation health risk management. Kumagai A; Reiners C; Drozd V; Yamashita S Endocr J; 2007 Dec; 54(6):839-47. PubMed ID: 17938505 [TBL] [Abstract][Full Text] [Related]
26. Thyroid cancer risk after thyroid examination with 131I: a population-based cohort study in Sweden. Dickman PW; Holm LE; Lundell G; Boice JD; Hall P Int J Cancer; 2003 Sep; 106(4):580-587. PubMed ID: 12845656 [TBL] [Abstract][Full Text] [Related]
27. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. Brown AP; Chen J; Hitchcock YJ; Szabo A; Shrieve DC; Tward JD J Clin Endocrinol Metab; 2008 Feb; 93(2):504-15. PubMed ID: 18029468 [TBL] [Abstract][Full Text] [Related]
28. The carcinogenic effects of radioiodine therapy for thyroid carcinoma. de Vathaire F Nat Clin Pract Endocrinol Metab; 2008 Apr; 4(4):180-1. PubMed ID: 18283326 [No Abstract] [Full Text] [Related]
29. Risk of second malignancies among survivors of pediatric thyroid cancer. Adly MH; Sobhy M; Rezk MA; Ishak M; Afifi MA; Shafie AE; Ali MA; Zekri W; Alfaar AS; Rashed WM Int J Clin Oncol; 2018 Aug; 23(4):625-633. PubMed ID: 29492793 [TBL] [Abstract][Full Text] [Related]
30. Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre Study. Piscopo L; Volpe F; Nappi C; Zampella E; Manganelli M; Matrisciano F; Totaro P; Pace L; Maurea S; Cuocolo A; Klain M Curr Oncol; 2022 Dec; 30(1):37-44. PubMed ID: 36661652 [TBL] [Abstract][Full Text] [Related]
31. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence. Reinecke MJ; Ahlers G; Burchert A; Eilsberger F; Flux GD; Marlowe RJ; Mueller HH; Reiners C; Rohde F; van Santen HM; Luster M Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3247-3256. PubMed ID: 35320386 [TBL] [Abstract][Full Text] [Related]
32. Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer. Kim KJ; Kim KJ; Choi J; Kim NH; Kim SG J Natl Cancer Inst; 2023 Jun; 115(6):695-702. PubMed ID: 36821433 [TBL] [Abstract][Full Text] [Related]
33. Subsequent malignancies in patients treated with 131-iodine for thyroid cancer. Glanzmann C Strahlenther Onkol; 1992 Jun; 168(6):337-43. PubMed ID: 1621212 [TBL] [Abstract][Full Text] [Related]
34. A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations. Brown AP; Neeley ES; Werner T; Soisson AP; Burt RW; Gaffney DK Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):127-35. PubMed ID: 19910129 [TBL] [Abstract][Full Text] [Related]
35. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up. Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613 [No Abstract] [Full Text] [Related]
36. Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients. Mei X; Yao X; Feng F; Cheng W; Wang H BMC Cancer; 2021 May; 21(1):543. PubMed ID: 33980182 [TBL] [Abstract][Full Text] [Related]
37. Salivary gland malignancy and radioiodine therapy for thyroid cancer. Klubo-Gwiezdzinska J; Van Nostrand D; Burman KD; Vasko V; Chia S; Deng T; Kulkarni K; Wartofsky L Thyroid; 2010 Jun; 20(6):647-51. PubMed ID: 20470209 [TBL] [Abstract][Full Text] [Related]
38. Risk of second bone sarcoma following childhood cancer: role of radiation therapy treatment. Schwartz B; Benadjaoud MA; Cléro E; Haddy N; El-Fayech C; Guibout C; Teinturier C; Oberlin O; Veres C; Pacquement H; Munzer M; N'guyen TD; Bondiau PY; Berchery D; Laprie A; Hawkins M; Winter D; Lefkopoulos D; Chavaudra J; Rubino C; Diallo I; Bénichou J; de Vathaire F Radiat Environ Biophys; 2014 May; 53(2):381-90. PubMed ID: 24419490 [TBL] [Abstract][Full Text] [Related]
39. Dual malignancies in the setting of differentiated thyroid carcinoma: their synchronous or metachronous nature, impact of radioiodine treatment on occurrence of second malignancy and other associated variables. Gandhi S; Abhyankar A; Basu S Nucl Med Commun; 2014 Feb; 35(2):205-9. PubMed ID: 24217429 [TBL] [Abstract][Full Text] [Related]
40. Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancy. Haddy N; Andriamboavonjy T; Paoletti C; Dondon MG; Mousannif A; Shamsaldin A; Doyon F; Labbé M; Robert C; Avril MF; Fragu P; Eschwege F; Chavaudra J; Schvartz C; Lefkopoulos D; Schlumberger M; Diallo I; de Vathaire F Radiother Oncol; 2009 Nov; 93(2):377-82. PubMed ID: 19515442 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]